<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303108</url>
  </required_header>
  <id_info>
    <org_study_id>04111</org_study_id>
    <nct_id>NCT00303108</nct_id>
  </id_info>
  <brief_title>Doxil &amp; Carboplatin Plus HER2+ in Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tibotec Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>US Oncology Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the ORR associated with Doxil in combination with
      carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.</time_frame>
    <description>Duration from date of stating treatment to the date of first CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
Progression is defined as appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of &quot;non-target&quot; lesions only is exceptional, in such circumstances, the opinion of the Treating Physician should prevail, and the progression status should be confirmed at a later time by the review panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>30 mg/m2 IV on Day 1 of each 28 day cycle</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=5 on Day 1 of each 28 day cycle</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has metastatic breast cancer with documented HER2- or HER2+ (IHC3+ or FISH+) disease

          -  Has measurable MBC, with at least 1 measurable lesion per RECIST criteria (see Section
             10). Irradiated lesions cannot be used to assess response but can be used to assess
             progression.

          -  Has had no prior treatment with Doxil or carboplatin; may have had adjuvant Herceptin
             if treatment was completed more than 1 year prior to study

          -  Has had no adjuvant chemotherapy within 1 year prior to study, but may have received
             prior anthracyclines as adjuvant chemotherapy

          -  For taxane-pretreated patients (adjuvant or metastatic), has had no more than 1 prior
             chemotherapy regimen for MBC

          -  For taxane-na√Øve patients, has had no prior chemotherapy for MBC

          -  Has had cumulative doses of &lt; 300 mg/m2 prior doxorubicin or &lt; 450 mg/m2 prior
             epirubicin

          -  Has normal cardiac function as evidenced by a LVEF within institutional normal limits
             by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO) may be used if
             MUGA is not available, but the same test must be used throughout the study to evaluate
             LVEF.

          -  Has an ECOG Performance Status (PS) 0-2 (see Appendix I)

          -  Is a male or female greater than or equal to 18 years of age

          -  Laboratory Values - Please refer to protocol section 4.2 for specific laboratory
             values.

          -  Has a negative serum pregnancy test within 7 days prior to registration (woman of
             childbearing potential [WOCBP; not surgically sterilized and between menarche and 1
             year postmenopause])

          -  If fertile, patient (male or female) has agreed to use an acceptable method of birth
             control (eg, abstinence, intrauterine device, oral contraceptives, barrier device with
             spermicide or surgical sterilization) to avoid pregnancy for the duration of the study
             and for a period of 3 months thereafter.

          -  Has signed a Patient Informed Consent Form

          -  Has signed a Patient Authorization Form (HIPAA Form)

          -  Has a life expectancy of &gt; 3 months

        Exclusion Criteria:

          -  Has had a myocardial infarction (MI) within 6 months of trial enrollment, or has New
             York Heart Association (NYHA; see Appendix IV) Class II or greater heart failure,
             uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically
             significant pericardial disease, or electrocardiographic evidence of acute ischemic or
             active conduction system abnormalities

          -  Has a history of hypersensitivity reactions attributed to a conventional formulation
             of doxorubicin HCL or the components of Doxil

          -  Has evaluable only disease; eg, bone only, pleural, peritoneal only disease

          -  Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy.
             Patients receiving immunosuppressant therapy for autoimmune disease may enroll on the
             trial after a drug washout period of 2 weeks.

          -  Is receiving concurrent investigational therapy or has received such therapy within 30
             days

          -  Has evidence of brain metastases requiring steroids and/or radiation or any documented
             leptomeningeal disease

          -  Has a serious uncontrolled intercurrent medical or psychiatric illness, including
             serious infection or history of uncontrolled seizures, CNS disorders deemed by the
             Treating Physician to be clinically significant, precluding informed consent

          -  Has a history of other malignancy within the last 5 years (except cured basal cell
             carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the
             diagnosis or assessment of any of the study drugs

          -  Is a pregnant or lactating woman

          -  Is unable to comply with requirements of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rufus P Collea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Hematology and Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern AZ Hematology &amp; Oncology Associates-Sedona</name>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center-Rose</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Institute</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of IL</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care &amp; Hematology Specialists of Chicagoland, PC</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers-Southwest</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, PA</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flavio Kruter, MD, PA</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <zip>21157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cancer Associates</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Associates</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth Oratz MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Hematology Oncology Associates</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Dayton Cancer Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Vallejy Cancer Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center - Abilene (South)</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.-Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mamie McFaddin Ward Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA-Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center at Medical City</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The TexasCancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center-Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Cancer Treatment Ctr</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Vista Cancer Center</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cancer Center-McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center of Mesquite</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alison Cancer Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Texas Cancer Center</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Regional Cancer Center</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOAST-Medical Dr.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center-Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Care and Research Center-Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Northern VA Hem-Onc PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onc and Hem Associates of SW VA, Inc</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Cancer Center-Edmonds</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Cancer Center-Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest-North</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Mem Hosp/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2006</study_first_posted>
  <results_first_submitted>February 2, 2016</results_first_submitted>
  <results_first_submitted_qc>September 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2016</results_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D+C and Taxane Naive</title>
          <description>Doxil, Carboplatin and Taxane naive</description>
        </group>
        <group group_id="P2">
          <title>D+C and Taxane Pretreated</title>
          <description>Doxil, Carboplatin and Taxane pretreated</description>
        </group>
        <group group_id="P3">
          <title>D+C+H</title>
          <description>Doxil, Carboplatin, and Herceptin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Request</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Entry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>D+C and Taxane Naive</title>
          <description>Doxil, Carboplatin and Taxane naive</description>
        </group>
        <group group_id="B2">
          <title>D+C and Taxane Pretreated</title>
          <description>Doxil, Carboplatin and Taxane pretreated</description>
        </group>
        <group group_id="B3">
          <title>D+C+H</title>
          <description>Doxil, Carboplatin, and Herceptin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" lower_limit="28.0" upper_limit="84.9"/>
                    <measurement group_id="B2" value="51.7" lower_limit="29.8" upper_limit="72.3"/>
                    <measurement group_id="B3" value="54.1" lower_limit="29.0" upper_limit="77.6"/>
                    <measurement group_id="B4" value="56.4" lower_limit="28.0" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.</time_frame>
        <population>Evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>D+C and Taxane Naive</title>
            <description>Doxil, Carboplatin and Taxane naive</description>
          </group>
          <group group_id="O2">
            <title>D+C and Taxane Pretreated</title>
            <description>Doxil, Carboplatin and Taxane pretreated</description>
          </group>
          <group group_id="O3">
            <title>D+C+H</title>
            <description>Doxil, Carboplatin, and Herceptin</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.</description>
          <population>Evaluable population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" lower_limit="17.0" upper_limit="47.6"/>
                    <measurement group_id="O2" value="31.0" lower_limit="17.6" upper_limit="47.1"/>
                    <measurement group_id="O3" value="55.6" lower_limit="40.0" upper_limit="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration from date of stating treatment to the date of first CR or PR.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.</time_frame>
        <population>Patients who achieved CR or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>D+C and Taxane Naive</title>
            <description>Doxil, Carboplatin and Taxane naive</description>
          </group>
          <group group_id="O2">
            <title>D+C and Taxane Pretreated</title>
            <description>Doxil, Carboplatin and Taxane pretreated</description>
          </group>
          <group group_id="O3">
            <title>D+C+H</title>
            <description>Doxil, Carboplatin, and Herceptin</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration from date of stating treatment to the date of first CR or PR.</description>
          <population>Patients who achieved CR or PR.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="0.9" upper_limit="15.2"/>
                    <measurement group_id="O2" value="7.0" lower_limit="2.8" upper_limit="13.2"/>
                    <measurement group_id="O3" value="11.8" lower_limit="2.3" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
Progression is defined as appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of ‚Äúnon-target‚Äù lesions only is exceptional, in such circumstances, the opinion of the Treating Physician should prevail, and the progression status should be confirmed at a later time by the review panel.</description>
        <time_frame>30 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>D+C and Taxane Naive</title>
            <description>Doxil, Carboplatin and Taxane naive</description>
          </group>
          <group group_id="O2">
            <title>D+C and Taxane Pretreated</title>
            <description>Doxil, Carboplatin and Taxane pretreated</description>
          </group>
          <group group_id="O3">
            <title>D+C+H</title>
            <description>Doxil, Carboplatin, and Herceptin</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
Progression is defined as appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of ‚Äúnon-target‚Äù lesions only is exceptional, in such circumstances, the opinion of the Treating Physician should prevail, and the progression status should be confirmed at a later time by the review panel.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="0.3" upper_limit="28.5"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.1" upper_limit="21.0"/>
                    <measurement group_id="O3" value="10.1" lower_limit="0.2" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-year Overall Survival</title>
        <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>D+C and Taxane Naive</title>
            <description>Doxil, Carboplatin and Taxane naive</description>
          </group>
          <group group_id="O2">
            <title>D+C and Taxane Pretreated</title>
            <description>Doxil, Carboplatin and Taxane pretreated</description>
          </group>
          <group group_id="O3">
            <title>D+C+H</title>
            <description>Doxil, Carboplatin, and Herceptin</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Overall Survival</title>
          <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
          <population>ITT population</population>
          <units>probability of overall survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.67" upper_limit="0.915"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.40" upper_limit="0.69"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.76" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the whole treatment period, up to 30 days following last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>D+C and Taxane Naive or Pretreated</title>
          <description>Doxil, Carboplatin and Taxane naive or pretreated.</description>
        </group>
        <group group_id="E2">
          <title>D+C+H</title>
          <description>Doxil, Carboplatin, and Herceptin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART, CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NAUSEA AND VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART, CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="152" subjects_affected="48" subjects_at_risk="83"/>
                <counts group_id="E2" events="90" subjects_affected="30" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LEUCOPENIA</sub_title>
                <counts group_id="E1" events="64" subjects_affected="21" subjects_at_risk="83"/>
                <counts group_id="E2" events="75" subjects_affected="18" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="177" subjects_affected="40" subjects_at_risk="83"/>
                <counts group_id="E2" events="145" subjects_affected="26" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="139" subjects_affected="35" subjects_at_risk="83"/>
                <counts group_id="E2" events="82" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="83"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="88" subjects_affected="43" subjects_at_risk="83"/>
                <counts group_id="E2" events="44" subjects_affected="29" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="27" subjects_affected="16" subjects_at_risk="83"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>WEAKNESS</sub_title>
                <counts group_id="E1" events="85" subjects_affected="40" subjects_at_risk="83"/>
                <counts group_id="E2" events="41" subjects_affected="23" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="20" subjects_affected="10" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PAIN BONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NEUROPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HAND-FOOT SYNDROME</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rufus Collea</name_or_title>
      <organization>New York Oncology Hematology, Albany Medical Center</organization>
      <phone>518-262-6696</phone>
      <email>rufus.collea@usoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

